| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 12/19/2001 | EP0785781B1 Use of indole derivatives for the treatment of dermatological disorders peripheral neuropathied, arthritis, allergic or chronic obstructive airways disease, glaucoma and ocular inflammation |
| 12/19/2001 | EP0781281B1 Beta-carboline derivatives as melatonin agonists, methods for their preparation and their use as drugs |
| 12/19/2001 | EP0721449B1 Inhibitors of beta-amyloid protein production |
| 12/19/2001 | EP0659073B1 Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
| 12/19/2001 | CN1327383A Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
| 12/19/2001 | CN1327382A Improved formulation for topical non-invasive application in vivo |
| 12/19/2001 | CN1326774A Compound brain nourishing liquid and its preparing method |
| 12/19/2001 | CN1326749A Insomnic plaster |
| 12/19/2001 | CN1076348C 3-bustituted oxindole derivatives as patassium path regulating agent |
| 12/18/2001 | USRE37478 1-(arylthioalkyl, arylaminoalkyl, or arylmethylenealkyl)-4-(heteroaryl)piperazines and related compounds useful as antipsychotics and analgesics |
| 12/18/2001 | US6331640 Diaminopropionic acid derivatives |
| 12/18/2001 | US6331636 Treatment of central nervous system disorders, diabetes, hypertension, impotency, appetite control |
| 12/18/2001 | US6331571 Methods of treating and preventing attention deficit disorders |
| 12/18/2001 | US6331568 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid |
| 12/18/2001 | US6331561 Use of substituted amino-methyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration |
| 12/18/2001 | US6331556 Benzofuran-4-carboxylic acid amide derivatives used as phosphodiesterase iv or tumor necrosis factor inhibitors |
| 12/18/2001 | US6331546 Use of 2-amino-3,4-dihydroquinazolines for the production of a medicament for the treatment or prophylaxis of illnesses caused by ischemic conditions |
| 12/18/2001 | US6331544 Treating positive and negative symptoms of schizophrenia and other psychoses |
| 12/18/2001 | US6331536 Administering to patient in need thereof effective amount of serotonin receptor antagonist to prevent or ameliorate sleep-related breathing disorder |
| 12/18/2001 | US6331410 Polynucleotides encoding a novel pyrR homolog |
| 12/18/2001 | US6331317 Pumping active agent and polymer through static mixer forming an emulsion, flowing through a manifold into quench liquid forming microparticles |
| 12/18/2001 | CA2213815C Pyrrolidinyl hydroxamic acid compounds and their production process |
| 12/18/2001 | CA2202484C Use of indole derivatives for the treatment of various diseases |
| 12/18/2001 | CA2178161C Indole derivatives |
| 12/18/2001 | CA2166470C Pharmacologically active enantiomers |
| 12/18/2001 | CA2057917C New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof |
| 12/13/2001 | WO2001094636A2 Compositions, kits, and methods for identification and modulation of type i diabetes |
| 12/13/2001 | WO2001094612A2 Method for identifying medically valuable active substances |
| 12/13/2001 | WO2001094586A2 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 12/13/2001 | WO2001094582A1 Novel g protein-coupled receptor protein and dna thereof |
| 12/13/2001 | WO2001094420A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 12/13/2001 | WO2001094415A2 Nuclear hormone receptor |
| 12/13/2001 | WO2001094414A2 THE HUMAN VOLTAGE GATED SODIUM CHANNEL β-1A SUBUNIT AND METHODS OF USE |
| 12/13/2001 | WO2001094413A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | WO2001094405A1 A new polypeptide- nerve synapse ion channel-associated chapsyn-110 and the polynucleotide encoding it |
| 12/13/2001 | WO2001094391A2 Intracellular signaling proteins |
| 12/13/2001 | WO2001094368A1 2-aminocarbonyl-9h-purine derivatives |
| 12/13/2001 | WO2001094351A1 Caspase inhibitors and uses thereof |
| 12/13/2001 | WO2001094346A1 1,3,8-TRIAZA-SPIRO'4,5!DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS |
| 12/13/2001 | WO2001094325A1 2-aminothiazoline derivatives and their use as no-synthase inhibitors |
| 12/13/2001 | WO2001094321A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists |
| 12/13/2001 | WO2001094319A1 Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors |
| 12/13/2001 | WO2001094311A1 Cytoprotectors |
| 12/13/2001 | WO2001094307A1 Propanolaminotetralines, preparation thereof and compositions containing same |
| 12/13/2001 | WO2001094306A2 (bis)sulfonamide derivatives |
| 12/13/2001 | WO2001094293A2 Benzamide ligands for the thyroid receptor |
| 12/13/2001 | WO2001093911A2 Macromolecular drug complexes and compositions containing the same |
| 12/13/2001 | WO2001093904A1 Method of treating gastrointestinal diseases associated with species of genus clostridium |
| 12/13/2001 | WO2001093896A2 A method of treatment of alzheimer's disease with a protein extractable from mammalian organs |
| 12/13/2001 | WO2001093895A2 A method of treatment of huntington's chorea with a protein extractable from mammalian organs |
| 12/13/2001 | WO2001093894A2 A method of treatment of parkinson's disease with a protein extractable from mammalian organs |
| 12/13/2001 | WO2001093893A2 The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
| 12/13/2001 | WO2001093890A2 Botulinum toxin implant |
| 12/13/2001 | WO2001093888A2 A method of treatment of amyotrophic lateral sclerosis with a protein extractable from mammalian organs |
| 12/13/2001 | WO2001093885A1 Therapeutic agents - ii |
| 12/13/2001 | WO2001093884A1 Therapeutic agents - i |
| 12/13/2001 | WO2001093883A1 Therapeutic agents - iii |
| 12/13/2001 | WO2001093869A1 Sildenafil and nicotine, synergistic association for neurodegenerative diseases |
| 12/13/2001 | WO2001093868A1 Buprenorphine-containing patch |
| 12/13/2001 | WO2001093867A1 4,5-dihydro-thiazo-2-ylamine derivatives and their use as no-synthase inhibitors |
| 12/13/2001 | WO2001093865A2 Medicaments for treating dementia |
| 12/13/2001 | WO2001093863A2 Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression |
| 12/13/2001 | WO2001093857A1 Composition for pain mediation and apparatus and method of use thereof |
| 12/13/2001 | WO2001093852A2 Method of treating pain using nalbuphine and opioid antagonists |
| 12/13/2001 | WO2001093849A2 Treatment of gastroesophageal reflux disease using piperidine derivatives |
| 12/13/2001 | WO2001093836A2 Encapsulation of polynucleotides and drugs into targeted liposomes |
| 12/13/2001 | WO2001093828A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| 12/13/2001 | WO2001093827A2 Neurotoxin implant |
| 12/13/2001 | WO2001093802A2 Use of riluzole or its salts for preventing and treating adrenoleukodystrophy |
| 12/13/2001 | WO2001085145A8 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| 12/13/2001 | WO2001068140A3 Opioid formulations |
| 12/13/2001 | WO2001055103A3 Chimeric neuropeptide y receptors |
| 12/13/2001 | WO2001049275A3 Methods and compositions for mitigating pain using nitrate esters |
| 12/13/2001 | WO2001047508A3 Combination of trimebutine with an opioid analgesic |
| 12/13/2001 | WO2001045637A3 Novel 4(piperazinyl (8-quinolinyl)metyl)benzamides |
| 12/13/2001 | WO2001044445A3 Human lyases and associated proteins |
| 12/13/2001 | WO2001044200A3 Selective neurokinin antagonists |
| 12/13/2001 | WO2001042784A3 Methods for screening compounds active on neurons |
| 12/13/2001 | WO2001041709A3 Methods for treating cell death diseases and inflammation |
| 12/13/2001 | WO2001041701A3 The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist |
| 12/13/2001 | WO2001040243A3 Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives |
| 12/13/2001 | WO2001039742A3 Methods for making sustained-release pharmaceutical compositions of ergot alkaloids having improved bioavailability and compositions thereof |
| 12/13/2001 | WO2001032647A3 Benz`f!indoles for use in the treatment of 5ht receptor related disorders |
| 12/13/2001 | WO2001029017A3 N-SUBSTITUTED 3-AMINO-2,2-DI-C-ALKYL-1,4-BUTYROLACTONES AND 1,4-THIOBUTYROLACTONES FOR USE AS PROMOTER OF η-AMINOBUTYRIC ACID ACTIVITY AND FOR TREATING NERVOUS DISORDERS AND PREPARATION METHOD |
| 12/13/2001 | WO2001025219A3 Piperazine compounds |
| 12/13/2001 | WO2000044888A3 Dimethylarginine dimethylaminohydrolases |
| 12/13/2001 | WO2000014115A9 Mc4-r as target for the identification of compounds used to treat drug addiction |
| 12/13/2001 | US20010051718 Reacting a 3 substituted 2-amino-pyridine with N-methyl-1-phenyl-2,2'-iminodiethyl halide, then adding ring closing agent to form mirtazepine; antidepressant |
| 12/13/2001 | US20010051653 Method for improving disturbancies of activities of daily living after stroke |
| 12/13/2001 | US20010051626 Substituted 1,2,3,4-tetrahydronaphthalene derivatives |
| 12/13/2001 | US20010051623 8-(Piperidin-4-yl- or piperazin-1-yl)-2-substituted-tetralin derivatives; selective effect at a subgroup of 5-hydroxytryptamine receptors, h5-HT1B receptors (previously 5-HT1D beta); antagonists; mood disorders, antianxiolytic |
| 12/13/2001 | US20010051602 Alzheimer's disease; adjust apolipoprotein concentration |
| 12/13/2001 | US20010051368 Methods of inhibiting the effects of amyloidogenic proteins |
| 12/13/2001 | US20010051152 Somnogenic activity |
| 12/13/2001 | DE10027968A1 Adjuvant therapy of dementia using alpha-lipoic acid or derivative, is effective in combination with antidementia or neurotransmission improving agents in improving cognitive function in e.g. Alzheimer's disease patients |
| 12/13/2001 | DE10027170A1 Humanes PEM als Target für die Fertilitätskontrolle Human PEM as a target for fertility control |
| 12/13/2001 | CA2810249A1 Identification and use of human bone marrow-derived endothelial progenitor cell to improve myocardial function after ischemic injury |
| 12/13/2001 | CA2412436A1 Identification and use of human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury |
| 12/13/2001 | CA2412377A1 B7-related nucleic acids and polypeptides and their uses for immunomodulation |
| 12/13/2001 | CA2411596A1 Therapeutic agents - ii |